{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:41:14Z","timestamp":1793677274393,"version":"4.5.1"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014042","name":"DOD Peer Reviewed Cancer Research Program","doi-asserted-by":"publisher","award":["GR023242"],"award-info":[{"award-number":["GR023242"]}],"id":[{"id":"10.13039\/100014042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40259-025-00735-z","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T17:12:53Z","timestamp":1754068373000},"page":"793-814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline"],"prefix":"10.1007","volume":"39","author":[{"given":"Toral","family":"Shastri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaad","family":"Trabolsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artavazd","family":"Arumov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1842-228X","authenticated-orcid":false,"given":"Jonathan H.","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"735_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57\u201366.","journal-title":"Lancet Oncol"},{"key":"735_CR2","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera J-M, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347.","journal-title":"N Engl J Med"},{"key":"735_CR3","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","volume":"95","author":"A L\u00f6ffler","year":"2000","unstructured":"L\u00f6ffler A, Kufer P, Lutterb\u00fcse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecific single-chain antibody, CD19 \u00d7 CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95:2098\u2013103.","journal-title":"Blood"},{"key":"735_CR4","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T Cell\u2013engaging antibody. Science. 2008;321:974\u20137.","journal-title":"Science"},{"key":"735_CR5","unstructured":"BLINCYTO\u00ae (blinatumomab) for injection."},{"key":"735_CR6","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331.","journal-title":"Blood"},{"key":"735_CR7","doi-asserted-by":"publisher","unstructured":"Dasatinib\u2013Blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med [Internet]. https:\/\/doi.org\/10.1056\/NEJMoa2016272","DOI":"10.1056\/NEJMoa2016272"},{"key":"735_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391:320\u201333.","journal-title":"N Engl J Med"},{"key":"735_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2411680","volume":"392","author":"S Gupta","year":"2025","unstructured":"Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, et al. Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. N Engl J Med. 2025;392:875\u201391.","journal-title":"N Engl J Med"},{"key":"735_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1158\/1535-7163.MCT-17-0657","volume":"17","author":"D Mandikian","year":"2018","unstructured":"Mandikian D, Takahashi N, Lo AA, Li J, Eastham-Anderson J, Slaga D, et al. Relative target affinities of T-cell\u2013dependent bispecific antibodies determine biodistribution in a solid tumor mouse model. Mol Cancer Ther. 2018;17:776\u201385.","journal-title":"Mol Cancer Ther"},{"key":"735_CR11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/bjc.1998.518","volume":"78","author":"MP Velders","year":"1998","unstructured":"Velders MP, van Rhijn CM, Oskam E, Fleuren GJ, Warnaar SO, Litvinov SV. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. Br J Cancer. 1998;78:478\u201383.","journal-title":"Br J Cancer"},{"key":"735_CR12","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/bloodadvances.2018019034","volume":"2","author":"AS Stein","year":"2018","unstructured":"Stein AS, Larson RA, Schuh AC, Stevenson W, Lech-Maranda E, Tran Q, et al. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Adv. 2018;2:1522\u201331.","journal-title":"Blood Adv"},{"key":"735_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","volume":"11","author":"ND Trinklein","year":"2019","unstructured":"Trinklein ND, Pham D, Schellenberger U, Buelow B, Boudreau A, Choudhry P, et al. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies. MAbs. 2019;11:639\u201352.","journal-title":"MAbs"},{"key":"735_CR14","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot A, Goebeler M-E, Hess G, Neumann S, Pfreundschuh M, Adrian N, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2016;127:1410\u20136.","journal-title":"Blood"},{"key":"735_CR15","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","volume":"131","author":"F Zammarchi","year":"2018","unstructured":"Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, et al. ADCT-402, a PBD dimer\u2013containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018;131:1094\u2013105.","journal-title":"Blood"},{"key":"735_CR16","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2352-3026(24)00345-4","volume":"12","author":"JP Alderuccio","year":"2024","unstructured":"Alderuccio JP, Alencar AJ, Schatz JH, Kuker RA, Pongas G, Reis IM, et al. Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024;12:e23\u201334.","journal-title":"Lancet Haematol."},{"key":"735_CR17","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.2217\/fon.15.84","volume":"11","author":"N Bumma","year":"2015","unstructured":"Bumma N, Papadantonakis N, Advani AS. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia. Future Oncol. 2015;11:1729\u201339.","journal-title":"Future Oncol"},{"key":"735_CR18","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","volume":"92","author":"M Mack","year":"1995","unstructured":"Mack M, Riethm\u00fcller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci. 1995;92:7021\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"735_CR19","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","volume":"11","author":"KM Linton","year":"2024","unstructured":"Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11:e593-605.","journal-title":"Lancet Haematol."},{"key":"735_CR20","doi-asserted-by":"publisher","unstructured":"Pharmacokinetics of Monoclonal Antibodies-Ryman-2017-CPT: Pharmacometrics & Systems Pharmacology-Wiley Online Library [Internet]. [cited 2025 Jun 22]. https:\/\/doi.org\/10.1002\/psp4.12224.","DOI":"10.1002\/psp4.12224"},{"key":"735_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002444","volume":"9","author":"M Poussin","year":"2021","unstructured":"Poussin M, Sereno A, Wu X, Huang F, Manro J, Cao S, et al. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies. J Immunother Cancer. 2021;9: e002444.","journal-title":"J Immunother Cancer"},{"key":"735_CR22","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-Cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023;41:2238\u201347.","journal-title":"J Clin Oncol"},{"key":"735_CR23","unstructured":"Karimi Y. 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab leads to deep and durable responses in relapsed or refractory large B-cell lymphoma. ASH; 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper198714.html. Accessed 24 Nov 2024."},{"key":"735_CR24","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","volume":"38","author":"C Thieblemont","year":"2024","unstructured":"Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024;38:2653\u201362.","journal-title":"Leukemia"},{"key":"735_CR25","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1182\/blood-2024-198714","volume":"144","author":"JM Vose","year":"2024","unstructured":"Vose JM, Cheah CY, Clausen MR, Cunningham D, Farooq U, Feldman T, et al. 3-Year update from the Epcore NHL-1 Trial: epcoritamab leads to deep and durable responses in relapsed or refractory large B-cell lymphoma. Blood. 2024;144:4480.","journal-title":"Blood"},{"key":"735_CR26","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1200\/JCO.23.02786","volume":"42","author":"MD Jain","year":"2024","unstructured":"Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, et al. Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2024;42:3581\u201392.","journal-title":"J Clin Oncol"},{"key":"735_CR27","doi-asserted-by":"crossref","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med [Internet]. 2022. https:\/\/www.nature.com\/articles\/s41591-022-01969-y. Accessed 28 Sept 2022.","DOI":"10.1038\/s41591-022-01969-y"},{"key":"735_CR28","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307\u201315.","journal-title":"Blood"},{"key":"735_CR29","doi-asserted-by":"publisher","first-page":"7039","DOI":"10.1200\/JCO.2024.42.16_suppl.7039","volume":"42","author":"Y Karimi","year":"2024","unstructured":"Karimi Y, Thieblemont C, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed\/refractory large B-cell lymphoma (R\/R LBCL). J Clin Oncol. 2024;42:7039\u20137039.","journal-title":"J Clin Oncol"},{"key":"735_CR30","doi-asserted-by":"publisher","first-page":"7037","DOI":"10.1200\/JCO.2024.42.16_suppl.7037","volume":"42","author":"JD Brody","year":"2024","unstructured":"Brody JD, Joergensen JM, Belada D, Costello R, Trneny M, Vitolo U, et al. Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2. J Clin Oncol. 2024;42:7037\u20137037.","journal-title":"J Clin Oncol"},{"key":"735_CR31","doi-asserted-by":"publisher","unstructured":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma | N Engl J Med [Internet]. https:\/\/doi.org\/10.1056\/NEJMoa2206913.","DOI":"10.1056\/NEJMoa2206913"},{"key":"735_CR32","unstructured":"Dickinson M. Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal phase II study. ASH; 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper194333.html. Accessed 21 Nov 2024."},{"key":"735_CR33","unstructured":"Genentech: Press Releases | Tuesday, May 20, 2025 [Internet]. https:\/\/www.gene.com\/media\/press-releases\/15061\/2025-05-20\/genentech-provides-update-on-fda-advisor?utm_source=chatgpt.com. Accessed 3 Jul 2025."},{"key":"735_CR34","unstructured":"May 20-21, 2025: Meeting of the Oncologic Drugs Advisory Committee-05\/20\/2025 [Internet]. FDA. 2025. https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025. Accessed 17 Jun 2025."},{"key":"735_CR35","unstructured":"Allan J. Indirect comparisons of the efficacy of epcoritamab vs glofitamab in patients (Pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL). ASH; 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper203994.html. Accessed 24 Nov 2024."},{"key":"735_CR36","unstructured":"Bartlett N. Subcutaneous mosunetuzumab leads to high rates of durable responses, low rates of cytokine release syndrome, and non-inferior exposure compared with intravenous administration in patients with Relapsed\/Refractory follicular lymphoma: primary analysis of a pivotal phase II. ASH; 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper194612.html. Accessed 20 Nov 2024."},{"key":"735_CR37","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood.2024025454","volume":"145","author":"LH Sehn","year":"2025","unstructured":"Sehn LH, Bartlett NL, Matasar MJ, Schuster SJ, Assouline SE, Giri P, et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies. Blood. 2025;145:708\u201319.","journal-title":"Blood"},{"key":"735_CR38","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055\u201365.","journal-title":"Lancet Oncol"},{"key":"735_CR39","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","volume":"7","author":"NL Bartlett","year":"2023","unstructured":"Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CY, Matasar M, et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2023;7:4926\u201335.","journal-title":"Blood Adv"},{"key":"735_CR40","unstructured":"Budde LE. Mosunetuzumab monotherapy demonstrates encouraging activity and a manageable safety profile in patients with heavily pre-treated relapsed or refractory mantle cell lymphoma. ASH; 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper197902.html. Accessed 20 Nov 2024."},{"key":"735_CR41","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/cts.13501","volume":"16","author":"ME Susilo","year":"2023","unstructured":"Susilo ME, Chi-Chung L, Gadkar K, Hernandez G, Huw L-Y, Jin JY, et al. Systems-based digital twins to help characterize clinical dose\u2013response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL. Clin Transl Sci. 2023;16:1134\u201348.","journal-title":"Clin Transl Sci"},{"key":"735_CR42","unstructured":"Odronextamab BLA accepted for FDA review for the treatment of relapsed\/refractory follicular lymphoma | Regeneron Pharmaceuticals Inc. [Internet]. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/odronextamab-bla-accepted-fda-review-treatment\/. Accessed 13 Jun 2025."},{"key":"735_CR43","unstructured":"FDA issues CRLs for odronextamab in R\/R Follicular Lymphoma and R\/R DLBCL [Internet]. OncLive. 2024. https:\/\/www.onclive.com\/view\/fda-issues-crls-for-odronextamab-in-r-r-follicular-lymphoma-and-r-r-dlbcl. Accessed 16 Oct 2024."},{"key":"735_CR44","unstructured":"OrdsponoTM (odronextamab) approved in the European Union for the treatment of relapsed\/refractory follicular lymphoma and diffuse large B-cell Lymphoma - Pipelinereview [Internet]. 2024. https:\/\/pipelinereview.com\/ordspono-odronextamab-approved-in-the-european-union-for-the-treatment-of-relapsed-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma\/. Accessed 18 Oct 2024."},{"key":"735_CR45","unstructured":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial - ClinicalKey [Internet]. https:\/\/www-clinicalkey-com.access.library.miami.edu\/#!\/content\/journal\/1-s2.0-S2352302622000722. Accessed 16 Oct 2024."},{"key":"735_CR46","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/blood-2023-179818","volume":"142","author":"S Ayyappan","year":"2023","unstructured":"Ayyappan S, Kim WS, Kim TM, Walewski J, Cho S-G, Jarque I, et al. Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-Cell lymphoma (DLBCL). Blood. 2023;142:436.","journal-title":"Blood"},{"key":"735_CR47","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood-2023-188064","volume":"142","author":"FG Haddad","year":"2023","unstructured":"Haddad FG, Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, et al. Chemotherapy-free combination of blinatumomab and ponatinib in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: updates from a phase II trial. Blood. 2023;142:2827.","journal-title":"Blood"},{"key":"735_CR48","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116:2040\u20135.","journal-title":"Blood"},{"key":"735_CR49","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:3121\u20137.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"735_CR50","doi-asserted-by":"publisher","first-page":"TPS7592","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7592","volume":"41","author":"LH Sehn","year":"2023","unstructured":"Sehn LH, Chamuleau M, Lenz G, Clausen M, Haioun C, Izutsu K, et al. Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2. J Clin Oncol. 2023;41:TPS7592.","journal-title":"J Clin Oncol"},{"key":"735_CR51","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1182\/blood-2024-198023","volume":"144","author":"L Falchi","year":"2024","unstructured":"Falchi L, Offner F, de Vos S, Brody J, Cordoba R, Linton K, et al. Fixed-duration epcoritamab + R-CHOP induces high complete response rates in patients with previously untreated diffuse large B-cell lymphoma withhigh-risk features: long-term results from the Epcore NHL-2 trial. Blood. 2024;144:581.","journal-title":"Blood"},{"key":"735_CR52","doi-asserted-by":"publisher","first-page":"e15870093","DOI":"10.1002\/hon.70093_158","volume":"43","author":"D Belada","year":"2025","unstructured":"Belada D, Kwiatek M, Bergua Burgues JM, Morschhauser F, Duell J, Jurczak W, et al. Epcore Dlbcl-3: Fixed-duration epcoritamab monotherapy in older (\u2265 75 Y), anthracycline-ineligible patients with previously untreated large B-cell lymphoma (LBCL). Hematol Oncol. 2025;43:e15870093.","journal-title":"Hematol Oncol"},{"key":"735_CR53","doi-asserted-by":"publisher","first-page":"e58270096","DOI":"10.1002\/hon.70096_582","volume":"43","author":"S Luminari","year":"2025","unstructured":"Luminari S, Brody JD, Falchi L, Bonello F, Nijland M, Offner F, et al. Epcoritamab plus bendamustine + rituximab for first-line treatment of follicular lymphoma: clinical and translational results from Epcore Nhl-2 Arm 3. Hematol Oncol. 2025;43:e58270096.","journal-title":"Hematol Oncol"},{"key":"735_CR54","doi-asserted-by":"publisher","first-page":"e22770094","DOI":"10.1002\/hon.70094_227","volume":"43","author":"R Merryman","year":"2025","unstructured":"Merryman R, Wallace DS, Redd R, Walker HA, Tringale R, Kats V, et al. Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: first results of a multicenter phase II Trial. Hematol Oncol. 2025;43:e22770094.","journal-title":"Hematol Oncol"},{"key":"735_CR55","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/blood-2023-174081","volume":"142","author":"MS Topp","year":"2023","unstructured":"Topp MS, Tani M, Dickinson M, Ghosh N, Santoro A, Pinto A, et al. Glofitamab plus R-CHOP induces high response rates with a manageable safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): a 12-month analysis from a phase Ib Study. Blood. 2023;142:3085.","journal-title":"Blood"},{"key":"735_CR56","doi-asserted-by":"publisher","first-page":"e7470093","DOI":"10.1002\/hon.70093_74","volume":"43","author":"JL Crombie","year":"2025","unstructured":"Crombie JL, Redd R, Forsyth M, Carey C, Mai J, Re S, et al. A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with high-risk diffuse large B-cell lymphoma. Hematol Oncol. 2025;43:e7470093.","journal-title":"Hematol Oncol"},{"key":"735_CR57","unstructured":"A phase 2 study of glofitamab and obinutuzumab for first-line treatment of follicular lymphoma and marginal zone lymphoma | Dana-Farber Cancer Institute [Internet]. https:\/\/www.dana-farber.org\/clinical-trials\/22-632. Accessed 25 Oct 2024."},{"key":"735_CR58","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1182\/blood-2023-174292","volume":"142","author":"RC Lynch","year":"2023","unstructured":"Lynch RC, Poh C, Shadman M, Till BG, Smith SD, Ujjani CS, et al. Early complete responses with mosunetuzumab monotherapy in treatment-na\u00efve follicular and marginal zone lymphomas with only low-grade cytokine release syndrome. Blood. 2023;142:4397.","journal-title":"Blood"},{"key":"735_CR59","doi-asserted-by":"publisher","first-page":"TPS7588","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7588","volume":"41","author":"AJ Olszewski","year":"2023","unstructured":"Olszewski AJ, Huntington SF, Ollila T, Pelcovits A, McMahon JB, Yakirevich I, et al. A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL). J Clin Oncol. 2023;41:TPS7588.","journal-title":"J Clin Oncol"},{"key":"735_CR60","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1182\/blood-2022-159396","volume":"140","author":"SC Oostindie","year":"2022","unstructured":"Oostindie SC, Alemdehy MF, Janmaat ML, Meerding JM, Kemper K, Engelberts PJ, et al. Duobody-CD3xCD30 demonstrates potent antitumor activity in preclinical models of CD30+ Hematologic malignancies. Blood. 2022;140:3153\u20134.","journal-title":"Blood"},{"key":"735_CR61","doi-asserted-by":"crossref","unstructured":"Maakaron J. Investigating the novel combination of the Innate Cell Engager (ICE\u00ae) acimtamig with off-the-shelf allogeneic natural killer cells AlloNK<sup>\u00ae<\/Sup> in relapsed or refractory classical Hodgkin lymphoma (R\/R cHL): initial results of the phase 2 Luminice-203 Study. ASH; 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper193896.html. Accessed 24 Dec 2024.","DOI":"10.1182\/blood-2024-193896"},{"key":"735_CR62","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","volume":"31","author":"Y Nieto","year":"2025","unstructured":"Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M, et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med. 2025;31:1987\u201393.","journal-title":"Nat Med"},{"key":"735_CR63","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00262-022-03267-5","volume":"72","author":"J Wang","year":"2023","unstructured":"Wang J, Li C, He K, Kuang Z, Lu J, Yao Y, et al. Characterization of anti-CD79b\/CD3 bispecific antibody, a potential therapy for B cell malignancies. Cancer Immunol Immunother. 2023;72:493\u2013507.","journal-title":"Cancer Immunol Immunother"},{"key":"735_CR64","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1182\/blood.V124.21.4507.4507","volume":"124","author":"LL Sun","year":"2014","unstructured":"Sun LL, Chen X, Chen Y, Dennis MS, Ellerman D, Johnson C, et al. Pre-clinical characterization of T cell-dependent bispecific antibody anti-CD79b\/CD3 as a potential therapy for B Cell malignancies. Blood. 2014;124:4507.","journal-title":"Blood"},{"key":"735_CR65","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207\u201321.","journal-title":"Lancet Oncol"},{"key":"735_CR66","unstructured":"Research C for DE and. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. FDA [Internet]. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma. Accessed 23 Oct 2024."},{"key":"735_CR67","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"735_CR68","doi-asserted-by":"publisher","first-page":"S548","DOI":"10.1016\/S2152-2650(24)01666-5","volume":"24","author":"AL Garfall","year":"2024","unstructured":"Garfall AL, Nooka AK, van de Donk NW, Moreau P, Bhutani M, Oriol A, et al. MM-336 long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2024;24:S548.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"735_CR69","unstructured":"TECVAYLI and TALVEY REMS - Home [Internet]. https:\/\/www.tec-talrems.com\/#Main. Accessed 22 Jan 2024."},{"key":"735_CR70","unstructured":"FDA grants accelerated approval to elranatamab-Bcmm for multiple myeloma [Internet]. ASCO. 2023. https:\/\/society.asco.org\/news-initiatives\/policy-news-analysis\/fda-grants-accelerated-approval-elranatamab-bcmm-multiple. Accessed 4 Nov 2024."},{"key":"735_CR71","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"735_CR72","unstructured":"Prince HM. MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma. ASH; 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper208192.html. Accessed 20 Nov 2024."},{"key":"735_CR73","unstructured":"Inc MG. Long-term survival after elranatamab monotherapy in patients with... by Dr. Mohamad Mohty [Internet]. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/420996\/mohamad.mohty.long-term.survival.after.elranatamab.monotherapy.in.patients.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Delranatamab. Accessed 4 Nov 2024."},{"key":"735_CR74","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1210\/en.2011-1504","volume":"153","author":"V-I Alexaki","year":"2012","unstructured":"Alexaki V-I, Pelekanou V, Notas G, Venihaki M, Kampa M, Dessirier V, et al. B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies. Endocrinology. 2012;153:739\u201349.","journal-title":"Endocrinology"},{"key":"735_CR75","unstructured":"Research C for DE and. FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma. FDA [Internet]. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma. Accessed 1 Mar 2024."},{"key":"735_CR76","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021;5:2196\u2013215.","journal-title":"Blood Adv"},{"key":"735_CR77","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1182\/blood-2021-146868","volume":"138","author":"AY Krishnan","year":"2021","unstructured":"Krishnan AY, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodriguez-Otero P, et al. Updated phase 1 results from MonumenTAL-1: First-in-human study of talquetamab, a g protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma. Blood. 2021;138:158.","journal-title":"Blood"},{"key":"735_CR78","unstructured":"Inc MG. Long-term efficacy and safety results from the phase 1\/2... by Dr. Leo Rasche [Internet]. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/420979\/leo.rasche.long-term.efficacy.and.safety.results.from.the.phase.1.2.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3D%23p915. Accessed 4 Nov 2024."},{"key":"735_CR79","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood-2021-153817","volume":"138","author":"SS Mancia","year":"2021","unstructured":"Mancia SS, Farrell A, Louw K, Florendo E, Aronson E, Purcell K, et al. Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab (JNJ-64407564) for the treatment of relapsed and\/or refractory multiple myeloma. Blood. 2021;138:1658.","journal-title":"Blood"},{"key":"735_CR80","unstructured":"Regeneron provides update on biologics license application for linvoseltamab | Regeneron Pharmaceuticals Inc. [Internet]. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-provides-update-biologics-license-application-0\/. Accessed 5 Nov 2024."},{"key":"735_CR81","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. | EBSCOhost [Internet]. 2015. p. 5. https:\/\/openurl.ebsco.com\/contentitem\/10.3322%2Fcaac.21254?sid=ebsco:plink:crawler&id=ebsco:10.3322%2Fcaac.21254. Accessed 1 Mar 2025."},{"key":"735_CR82","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-023-01474-w","volume":"16","author":"N Lopez-Mu\u00f1oz","year":"2023","unstructured":"Lopez-Mu\u00f1oz N, Hern\u00e1ndez-Ibarburu G, Alonso R, Sanchez-Pina JM, Ayala R, Calbacho M, et al. Large-scale real-life analysis of survival and usage of therapies in multiple myeloma. J Hematol OncolJ Hematol Oncol. 2023;16:76.","journal-title":"J Hematol OncolJ Hematol Oncol."},{"key":"735_CR83","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123:1826\u201332.","journal-title":"Blood"},{"key":"735_CR84","doi-asserted-by":"publisher","first-page":"e162590e","DOI":"10.1097\/01.HS9.0000970364.16259.0e","volume":"7","author":"C Tan","year":"2023","unstructured":"Tan C, Searle E, Anguille S, Bhutani M, Biran N, Boyd K, et al. P865: Teclistamab in Combination with lenalidomide in previously treated patients with multiple myeloma in the phase 1b multicohort Majestec-2 Study. HemaSphere. 2023;7:e162590e.","journal-title":"HemaSphere."},{"key":"735_CR85","doi-asserted-by":"publisher","first-page":"10148","DOI":"10.1182\/blood-2022-160173","volume":"140","author":"AY Krishnan","year":"2022","unstructured":"Krishnan AY, Manier S, Terpos E, Usmani S, Khan J, Pearson R, et al. MajesTEC-7: a phase 3, randomized study of teclistamab + daratumumab + lenalidomide (Tec-DR) versus daratumumab + lenalidomide + dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant. Blood. 2022;140:10148\u20139.","journal-title":"Blood"},{"key":"735_CR86","doi-asserted-by":"crossref","unstructured":"Nooka A. Talquetamab, a GPRC5D\u00c3\u2014CD3 bispecific antibody, in combination with daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma: safety and efficacy results from the Phase 1b Monumental-2 Study. ASH; 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper199773.html. Accessed 18 Nov 2024.","DOI":"10.1182\/blood-2024-199773"},{"key":"735_CR87","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/blood-2022-162733","volume":"140","author":"YC Cohen","year":"2022","unstructured":"Cohen YC, Moreau P, Tolbert J, Qin X, Ma X, Vieyra D, et al. MonumenTAL-3: phase 3 Trial of talquetamab + daratumumab \u00b1 pomalidomide versus daratumumab + pomalidomide + dexamethasone in relapsed\/refractory multiple myeloma following \u22651 prior line of therapy. Blood. 2022;140:4418\u20139.","journal-title":"Blood"},{"key":"735_CR88","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min C-K, et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2025;392:138\u201349.","journal-title":"N Engl J Med"},{"key":"735_CR89","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1182\/blood-2022-162738","volume":"140","author":"S Grosicki","year":"2022","unstructured":"Grosicki S, Mellqvist U-H, Pruchniewski \u0141, Crafoord J, Trudel S, Min C-K, et al. Elranatamab in Combination with daratumumab for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the phase 3 Magnetismm-5 Study Safety Lead-in Cohort. Blood. 2022;140:4407\u20138.","journal-title":"Blood"},{"key":"735_CR90","doi-asserted-by":"publisher","first-page":"TPS8065","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8065","volume":"41","author":"S Grosicki","year":"2023","unstructured":"Grosicki S, Yeh S-P, Huang JSY, Byun JM, DiRienzo C, Viqueira A. MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM). J Clin Oncol. 2023;41:TPS8065.","journal-title":"J Clin Oncol"},{"key":"735_CR91","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1182\/blood-2023-180013","volume":"142","author":"N Bar","year":"2023","unstructured":"Bar N, Mateos MV, Ribas P, Hansson M, Paris L, Hofmeister CC, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-cell maturation antigen (BCMA) \u00d7 CD3 T-cell engager (TCE), administered subcutaneously (SC) in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 first-in-human clinical study. Blood. 2023;142:2011.","journal-title":"Blood"},{"key":"735_CR92","unstructured":"An Interim Report on a Phase 1\/2 Study of HPN217, a half-life extended tri-specific t cell activating construct (TriTAC \u00ae) targeting B cell maturation antigen for the treatment of relapsed\/refractory multiple myeloma - ScienceDirect [Internet]. https:\/\/www-sciencedirect-com.access.library.miami.edu\/science\/article\/pii\/S0006497121036211. Accessed 12 Nov 2024"},{"key":"735_CR93","doi-asserted-by":"crossref","unstructured":"P937: Preclinical discovery and early findings from the phase 1, dose\u2010escalation study of WVT078, a BCMA\u2010CD3 bispecific antibody, in patients with R\/R multiple myeloma-Raab-2022-HemaSphere-Wiley Online Library [Internet]. https:\/\/doi.org\/10.1097\/01.HS9.0000846616.21003.5d?sid=vendor3Adatabase. Accessed 12 Nov 2024","DOI":"10.1097\/01.HS9.0000846616.21003.5d"},{"key":"735_CR94","doi-asserted-by":"publisher","unstructured":"A Phase I First-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-Cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma |J Clin Oncol [Internet]. https:\/\/doi.org\/10.1200\/JCO.22.01504. Accessed 12 Nov 2024","DOI":"10.1200\/JCO.22.01504"},{"key":"735_CR95","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/01.HS9.0000843648.44771.79","volume":"6","author":"JA Zonder","year":"2022","unstructured":"Zonder JA, Richter J, Bumma N, Brayer J, Hoffman JE, Bensinger WI, et al. S189: Early, deep, and durable responses, and low rates of CRs with REGN5458, a BCMAXCD3 bispecific antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma. HemaSphere. 2022;6:90.","journal-title":"HemaSphere."},{"key":"735_CR96","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11:eaau7746.","journal-title":"Sci Transl Med."},{"key":"735_CR97","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2022-157988","volume":"140","author":"C Carlo-Stella","year":"2022","unstructured":"Carlo-Stella C, Mazza R, Manier S, Facon T, Yoon S-S, Koh Y, et al. RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple Myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study. Blood. 2022;140:397\u20139.","journal-title":"Blood"},{"key":"735_CR98","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","volume":"138","author":"S Trudel","year":"2021","unstructured":"Trudel S, Cohen AD, Krishnan AY, Fonseca R, Spencer A, Berdeja JG, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Blood. 2021;138:157.","journal-title":"Blood"},{"key":"735_CR99","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1182\/blood-2023-186664","volume":"142","author":"P Kapoor","year":"2023","unstructured":"Kapoor P, Stevens DA, Leleu X, Belhadj Merzoug K, Karlin L, Manier S, et al. Dose escalation of ISB 1342, a novel CD38xCD3 bispecific antibody, in patients with relapsed \/ refractory multiple myeloma (RRMM). Blood. 2023;142:3339.","journal-title":"Blood"},{"key":"735_CR100","doi-asserted-by":"crossref","unstructured":"Initial Dose escalation of ISB 1442, a novel CD38 Biparatopic x CD47 bispecific antibody, in patients with relapsed \/ refractory multiple myeloma (RRMM) | Blood | Am Soc Hematol [Internet]. https:\/\/ashpublications.org\/blood\/article\/142\/Supplement%201\/4707\/499600\/Initial-Dose-Escalation-of-ISB-1442-a-Novel-CD38. Accessed 13 Nov 2024.","DOI":"10.1182\/blood-2023-186241"},{"key":"735_CR101","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.2023022432","volume":"143","author":"JL Crombie","year":"2024","unstructured":"Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, et al. Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy. Blood. 2024;143:1565\u201375.","journal-title":"Blood"},{"key":"735_CR102","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"735_CR103","unstructured":"Kowalski A. Tocilizumab prophylaxis for patients with relapsed or refractory multiple myeloma treated with teclistamab, elranatamab or talquetamab. ASH; 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper203426.html. Accessed 19 Nov 2024"},{"key":"735_CR104","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood.2022016243","volume":"140","author":"L Zhao","year":"2022","unstructured":"Zhao L, Li S, Wei X, Qi X, Liu D, Liu L, et al. A novel CD19\/CD22\/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood. 2022;140:1790\u2013802.","journal-title":"Blood"},{"key":"735_CR105","doi-asserted-by":"crossref","unstructured":"Xu Y. A phase I First-in-human, open-label trial to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of SIM0500, a humanized GPRC5D-BCMA-CD3 trispecific antibody, in participants with relapsed or refractory multiple myeloma. ASH; 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper200737.html. Accessed 25 Dec 2024","DOI":"10.1182\/blood-2024-200737"},{"key":"735_CR106","doi-asserted-by":"crossref","unstructured":"An G. MBS314, a G protein-coupled receptor family C group 5 member D (GPRC5D) x B-cell maturation antigen (BCMA) x CD3 trispecific antibody, in relapsed and\/or refractory multiple myeloma (RRMM): preliminary results from a phase I, first-in-human, open-label, dose escalation study. ASH; 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper199423.html. Accessed 25 Dec 2024.","DOI":"10.1182\/blood-2024-199423"},{"key":"735_CR107","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2025.43.16_suppl.7505","volume":"43","author":"NWCJ van de Donk","year":"2025","unstructured":"van de Donk NWCJ, Vega G, Perrot A, Anguille S, Oriol A, Minnema M, et al. First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial phase 1 results. J Clin Oncol. 2025;43:7505\u20137505.","journal-title":"J Clin Oncol"},{"key":"735_CR108","doi-asserted-by":"publisher","first-page":"7514","DOI":"10.1200\/JCO.2025.43.16_suppl.7514","volume":"43","author":"EI Lichtman","year":"2025","unstructured":"Lichtman EI, Khot A, Augustson B, Levitz D, Sia H, Wong Doo N, et al. Phase 1, first-in-human study of ISB 2001: a BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed\/refractory multiple myeloma (RRMM)\u2014Dose escalation (DE) results. J Clin Oncol. 2025;43:7514\u20137514.","journal-title":"J Clin Oncol"},{"key":"735_CR109","doi-asserted-by":"crossref","unstructured":"Hutchings M. Englumafusp Alfa (CD19-4-1BBL) Combined with glofitamab is safe and efficacious in patients with R\/R B-NHL: extended follow up analysis of the dose-escalation part of phase 1 trial BP41072. ASH; 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper200096.html. Accessed 25 Dec 2024","DOI":"10.1182\/blood-2024-200096"},{"key":"735_CR110","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1182\/blood.2023023381","volume":"143","author":"J Sam","year":"2024","unstructured":"Sam J, Hofer T, Kuettel C, Claus C, Thom J, Herter S, et al. CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy. Blood. 2024;143:2152\u201365.","journal-title":"Blood"},{"key":"735_CR111","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.immuni.2017.06.019","volume":"47","author":"H-S Dai","year":"2017","unstructured":"Dai H-S, Griffin N, Bolyard C, Mao HC, Zhang J, Cripe TP, et al. The Fc domain of immunoglobulin is sufficient to bridge NK cells with virally infected cells. Immunity. 2017;47:159-170.e10.","journal-title":"Immunity"},{"key":"735_CR112","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1080\/19420862.2015.1029216","volume":"7","author":"U Reusch","year":"2015","unstructured":"Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, et al. A tetravalent bispecific TandAb (CD19\/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7:584\u2013604.","journal-title":"MAbs"},{"key":"735_CR113","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jmb.2010.04.001","volume":"399","author":"S Johnson","year":"2010","unstructured":"Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol. 2010;399:436\u201349.","journal-title":"J Mol Biol"},{"key":"735_CR114","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","volume":"125","author":"A Rothe","year":"2015","unstructured":"Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:4024\u201331.","journal-title":"Blood"},{"key":"735_CR115","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002980","volume":"9","author":"C Zhang","year":"2021","unstructured":"Zhang C, R\u00f6der J, Scherer A, Bodden M, Serrahima JP, Bhatti A, et al. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity. J Immunother Cancer. 2021;9: e002980.","journal-title":"J Immunother Cancer"},{"key":"735_CR116","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1097\/CJI.0b013e318186c8b4","volume":"31","author":"C Kellner","year":"2008","unstructured":"Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, et al. A Novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother. 2008;31:871.","journal-title":"J Immunother"},{"key":"735_CR117","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00432-024-05740-3","volume":"150","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wang H, Sun C. BiSpec Pairwise AI: guiding the selection of bispecific antibody target combinations with pairwise learning and GPT augmentation. J Cancer Res Clin Oncol. 2024;150:237.","journal-title":"J Cancer Res Clin Oncol"},{"key":"735_CR118","doi-asserted-by":"publisher","first-page":"e50470096","DOI":"10.1002\/hon.70096_504","volume":"43","author":"AM Bock","year":"2025","unstructured":"Bock AM, Baron K, Wagner C, Fitzgerald L, Ermann D, Hu B, et al. Impact of the Neutrophil\/lymphocyte ratio on outcomes following bispecific antibody therapy in relapsed\/refractory lymphoma patients. Hematol Oncol. 2025;43:e50470096.","journal-title":"Hematol Oncol"},{"key":"735_CR119","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining \u2018T cell exhaustion.\u2019 Nat Rev Immunol. 2019;19:665\u201374.","journal-title":"Nat Rev Immunol"},{"key":"735_CR120","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/protein\/gzy007","volume":"31","author":"X Wu","year":"2018","unstructured":"Wu X, Yuan R, Bacica M, Demarest SJ. Generation of orthogonal Fab-based trispecific antibody formats. Protein Eng Des Sel. 2018;31:249\u201356.","journal-title":"Protein Eng Des Sel"},{"key":"735_CR121","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11899-024-00748-5","volume":"20","author":"PR Keesari","year":"2025","unstructured":"Keesari PR, Samuels D, Vegivinti CTR, Pulakurthi YS, Kudithi R, Dhar M, et al. Navigating the economic burden of multiple myeloma: insights into cost-effectiveness of CAR-T and Bispecific antibody therapies. Curr Hematol Malig Rep. 2025;20:3.","journal-title":"Curr Hematol Malig Rep"},{"key":"735_CR122","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","volume":"1","author":"L Wu","year":"2020","unstructured":"Wu L, Seung E, Xu L, Rao E, Lord DM, Wei RR, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat Cancer. 2020;1:86\u201398.","journal-title":"Nat Cancer."},{"key":"735_CR123","doi-asserted-by":"publisher","first-page":"9461","DOI":"10.1182\/blood-2022-157011","volume":"140","author":"M Hutchings","year":"2022","unstructured":"Hutchings M, Carlo-Stella C, Gritti G, Bosch F, Morschhauser F, Townsend W, et al. CD19 4\u20131BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-cell-engaging bispecific antibody glofitamab in relapsed or refractory B-cell non-Hodgkin lymphoma. Blood. 2022;140:9461\u20133.","journal-title":"Blood"},{"key":"735_CR124","doi-asserted-by":"crossref","unstructured":"Lawrence R. Pre-Clinical Evaluation of AZD5492, a novel CD8-guided T cell engager, for B-non Hodgkin lymphoma indications. ASH; 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper198745.html. Accessed 12 Jan 2025.","DOI":"10.1182\/blood-2024-198745"},{"key":"735_CR125","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1158\/1078-0432.CCR-24-1872","volume":"30","author":"AC Baines","year":"2024","unstructured":"Baines AC, Kanapuru B, Zhao J, Price LSL, Zheng N, Konicki R, et al. FDA approval summary: Teclistamab\u2014a bispecific CD3 T-cell engager for patients with relapsed or refractory multiple myeloma. Clin Cancer Res. 2024;30:5515\u201320.","journal-title":"Clin Cancer Res"},{"key":"735_CR126","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.136","volume":"8","author":"MH Tomasson","year":"2024","unstructured":"Tomasson MH, Iida S, Niesvizky R, Mohty M, Bahlis NJ, Martinez-Lopez J, et al. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study. HemaSphere. 2024;8: e136.","journal-title":"HemaSphere."},{"key":"735_CR127","doi-asserted-by":"publisher","first-page":"S561","DOI":"10.1016\/S2152-2650(24)01689-6","volume":"24","author":"L Rasche","year":"2024","unstructured":"Rasche L, Schinke C, Touzeau C, Minnema MC, van de Donk NWCJ, Rodr\u00edguez-Otero P, et al. MM-492 Long-term efficacy and safety results from the phase 1\/2 MonumenTAL-1 study of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2024;24:S561\u20132.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"735_CR128","doi-asserted-by":"crossref","unstructured":"Abstract CT001: Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups-University of Miami [Internet]. https:\/\/scholarship.miami.edu\/esploro\/outputs\/journalArticle\/Abstract-CT001-Linvoseltamab-a-B-cell-maturation\/991032064109802976?institution=01UOML_INST. Accessed 18 Jun 2025.","DOI":"10.1158\/1538-7445.AM2024-CT001"},{"key":"735_CR129","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1182\/blood-2023-180472","volume":"142","author":"N Goekbuget","year":"2023","unstructured":"Goekbuget N, Schwartz S, Faul C, Topp MS, Subklewe M, Renzelmann A, et al. Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with Ph\/BCR::ABL negative B-precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL Bold trial. Blood. 2023;142:964.","journal-title":"Blood"},{"key":"735_CR130","unstructured":"Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study-ClinicalKey [Internet]. https:\/\/www-clinicalkey-com.access.library.miami.edu\/#!\/content\/journal\/1-s2.0-S2473952923004548. Accessed 18 Jun 2025"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00735-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:53:45Z","timestamp":1757336025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00735-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":130,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["735"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00735-z","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"13 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A.T. and T.S. disclose no conflict of interest. A.A. is an employee at Qiming Venture Partners USA. J.H.S. declares consultancy\/advisory roles for Affimed, Acrotech, and WCG Clinical.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"T.S. and A.T. are the primary authors of the paper who drafted and edited the paper. A.A. and J.H.S. provided revisions to the content of the manuscript and conceived ideas for the design of the paper.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}},{"value":"No datasets were generated or analyzed during the current study.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}}]}}